Cellmid 2017 Annual Report
26
DIRECTORS’
REPORT
CONTINUED
Equity based compensation
Details of the options granted as remuneration to those key management personnel and executives during the year:
Options Value of Value of shares Proportion of
Granted & options at expensed remuneration
Vested in 2017 grant date in 2017
Share based payments No $ $ %
Directors
David King - - - -
Maria Halasz - - - -
Bruce Gordon - - - -
Fintan Walton - - - -
Options Value of Value of shares Proportion of
Granted & options at expensed remuneration
Vested in 2016 grant date in 2016
Share based payments No $ $ %
David King 4,000,000 27,200 27,200 27.65
Maria Halasz1 - - 73,667 13.35
Bruce Gordon 2,000,000 13,600 13,600 21.38
Fintan Walton 2,000,000 13,600 13,600 22.37
No equity-based compensation in the form of options over ordinary shares were issued during the year ended 30 June 2017.
1. On 25 November 2013, 12,000,000 loan shares were granted to Maria Halasz in three equal tranches under the Cellmid
Limited and Controlled Entities Employee Incentive Plan and as approved by shareholders at the annual general meeting
on 22 November 2013. Ordinary shares were issued under the arrangement funded by a limited recourse loan with the
following vesting conditions attached: